Ulcerative Colitis :: LIALDA – the first oral once-daily mesalamine for ulcerative colitis available
Shire plc today announced the availability of LIALDATM (mesalamine) with MMXTM Technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), a type of inflammatory bowel disease. LIALDA is the first and only FDA-approved once daily oral formulation of mesalamine. The US Food and Drug Administration approved LIALDA on Jan. 16, 2007.